The goal of this study was to examine the efficacy and safety of IOP-lowering travoprost 0.004 percent and travoprost 0.004 percent plus beta-blocker 0.5 percent fixed combination ophthalmic solution in patients with open-angle glaucoma and ocular hypertension.
Methods: In this
prospective, multicenter clinical trial, 62 patients were administered either
travoprost 0.004% (n = 31) or travoprost 0.004% with beta-blocker 0.50% (n =
31). Efficacy and safety were compared among treatment groups over a two-year period.
At 3, 6, 12, and 24 months, each group's IOP reduction and adverse events were
evaluated.
The mean IOP at the
first visit was 26.4 (SD 2.1) in the travoprost 0.004 percent group and 26.3
(SD 2.1) in the travoprost 0.004 percent/timolol 0.5 percent group. After 24
months, the mean IOP in the travoprost 0.004 percent group was 20.5 (SD 1.5),
while in the travoprost 0.004 percent/timolol 0.5 percent group was 18.5 (SD
1.5). After the third (after one year) and fourth visits, there were
statistically significant differences in IOP in both eyes (after 2 years).
Author(S) Details
Gentian Hoxha
Department of Ophthalmology, Faculty of Medicine, University Clinical Center of Kosovo, Prishtina, Kosovo.
Kelmend Spahiu
Department of Ophthalmology, Faculty of Medicine, University Clinical Center of Kosovo, Prishtina, Kosovo.
Gazmend Kaçaniku
Department of Ophthalmology, Faculty of Medicine, University Clinical Center of Kosovo, Prishtina, Kosovo.
Mimoza Ismaili
Department of Ophthalmology, Faculty of Medicine, University Clinical Center of Kosovo, Prishtina, Kosovo.
Fëllanza Ismajli-Hoxha
Department of Dermatovenerology, Faculty of Medicine, University Clinical Center of Kosovo, Prishtina, Kosovo.
View Book:- https://stm.bookpi.org/NHMMR-V2/article/view/6123
No comments:
Post a Comment